Heidi doubles valuation to $900m with $340m funding split between equity and revenue-share deal

Melbourne's Heidi has announced $340m in fresh funding at a $900m valuation, nearly doubling its previous valuation of $465m from October. The round splits into two distinct structures: Blackbird led a $100m Series C equity investment alongside Phoenix Court, Point72 Private Investments and Headline. The remaining $240m originates from General Catalyst's Customer Value Fund, a debt-like instrument that takes no equity stake.

"From the day I started Heidi, the ambition was always bigger than writing doctor's notes," said Dr Thomas Kelly, the company's cofounder, as the funding announcement went live on Tuesday.

How the General Catalyst structure works

General Catalyst's Customer Value Fund operates as a non-dilutive financing mechanism. The fund holds no shares, warrants or ownership stakes in Heidi. Instead, it finances sales and marketing activities, then captures a capped percentage of the revenue generated by that spending, alongside recovering its principal investment.

Pranav Singhvi, who cofounded the fund, explained that the instrument enables companies demonstrating strong unit economics to accelerate growth without depleting their own balance sheets. The equity portion of the round funds product development, regulatory work and other non-go-to-market expenses.

Heidi's total capital raised now stands at $436.6m.

The metrics driving the valuation

The company's annual recurring revenue climbed from $1m to $50m within two years, reaching that milestone in April. Patient visit volume supported by Heidi's platform has grown to more than 175 million, compared with 73 million at the Series B stage, alongside more than 67 million clinical hours logged.

Weekly patient interactions now reach approximately 2.8 million across 110 languages and 190 countries, expanding from 116 countries a year earlier. Enterprise activation rates stand near 62%, and the company employs close to 600 people.

Where Heidi operates today

In the UK, Heidi serves as the sole supplier to NHS England Midlands under what the company describes as the largest clinical AI procurement in NHS history. Across the Atlantic, Beth Israel Lahey Health in Massachusetts uses the platform. New Zealand has deployed Heidi across every emergency department in the country.

Australian installations include the Royal Children's Hospital Melbourne, Children's Health Queensland and Metro South Health.

What the funding enables

Kelly outlined plans to shift from documentation assistance toward autonomous agents that perform clinical work under clinician supervision. Within six to twelve months, he told Bloomberg, Heidi should handle the majority of tasks a doctor requests.

Rather than licensing third-party frontier models, Heidi has developed proprietary technology. Transcription and note generation, which consume most compute resources, now run almost entirely on in-house systems.

The company has already shipped Evidence, a tool answering clinical guideline questions that has fielded more than 10 million queries since March. It has also released Remote, an audio-capture wearable, and Dictate.

The funding also covers clinical evidence development, quality management systems and regulatory submissions. Heidi indicated it will engage with regulators to determine the appropriate approval pathway.

A notable geographic restriction

In a single line beneath investor quotes, Heidi stated that forthcoming product capabilities will not be available in the UK and EU. The company provided neither explanation nor timeline for this restriction.

Heidi holds ISO 27001, SOC 2 Type II, Cyber Essentials Plus and ISO 42001 certifications, alongside alignment with NHS requirements, GDPR, HIPAA and the Australian Privacy Principles.

The regulatory landscape for clinical AI

Europe's pathway for autonomous clinical AI remains lengthy. Vara spent years obtaining CE certification for AI technology that interprets breast screening images independently.

Clinical AI scrutiny has intensified. In August, reporting revealed that NHS AI scribes were introducing errors into patient records, prompting Healthwatch concerns and MHRA involvement. Separately, an AI receptionist mishandled a stroke patient case.

Heidi maintains that every autonomous decision remains subject to clinician control. Its clinical research team conducts testing, validation and publishes research before releasing new features.

Public acceptance remains uncertain. A 2023 Pew Research Center survey found that 60% of American adults would feel uncomfortable if their doctor relied on AI for diagnosis.

Competitive funding activity

Tandem Health raised $100m on 15 September to evolve its AI scribe into comprehensive clinic software—the same equity amount for an identical strategic pivot, announced one week prior.

Forus secured $150m this month at a $3bn valuation, while Latent raised $80m earlier in the year.

Kelly's competitive argument centers on retention. Healthcare demands extensive setup and configuration, and Heidi's data demonstrates that customers remain engaged with the platform.

The World Health Organization projects a shortage of 11 million health workers by 2030—the market gap Heidi targets with its offering.

Source: The Next Web